Annekathrin Haberland holds a PhD in pharmacy at the Humboldt-University of Berlin, Germany. She joined Berlin Cures in March 2015 as director of regulatory affairs, also being responsible for managing innovation and technology. The Berlin Cures Holding is a Life Science Company, located in Zug, Switzerland, which develops oligonucleotide-based therapeutic agents for the treatment of diseases which are associated with functionally active autoantibodies against G-protein coupled receptors (fGPCR-AAbs). Before joining Berlin Cures, Annekathrin worked at a Contract Development and Manufacturing Organization and technology provider in Berlin, the ProBioGen AG, as the innovation and technology manager. Before that, Annekathrin has held different scientist and senior scientist positions at universities and the Max-Delbrück-Center of Molecular Medicine, Berlin-Buch, Germany. Here she worked for an extended period of time in the laboratory of Priv.-Doz. Dr. Michael Böttger, where she developed non-viral DNA-vectors and studied protein-DNA-interaction. Consequently, Annekathrin introduced aptamer technology to fGPCR-AAbs and was thus an essential partner in laying the foundation for the later development of BC007.